TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME

被引：0
|
作者：
Mariette, X. [1 ]
Curtis, J. [2 ]
Lee, E. [3 ]
Benda, B. [4 ]
Kaplan, I. [5 ]
Soma, K. [5 ]
Kwok, K. [6 ]
Geier, J. [6 ]
Wang, L. [5 ]
Riese, R. [5 ]
机构：
[1] Univ Paris Sud, Hop Bicetre, Paris, France
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Seoul Natl Univ, Seoul, South Korea
[4] Pfizer Inc, Collegeville, PA USA
[5] Pfizer Inc, Groton, CT 06340 USA
[6] Pfizer Inc, New York, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.2139
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0147
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [21] EFFECTS OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, ON PATIENT-REPORTED OUTCOMES IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS
    Yamanaka, H.
    Tanaka, Y.
    Takeuchi, T.
    Sugiyama, N.
    Hirose, T.
    Yoshii, N.
    Morishima, Y.
    Toyoizumi, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 274 - 275
  • [22] Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis Pooled efficacy and safety analyses
    Lomonte, Andrea B. V.
    Radominski, Sebastiao C.
    Marcolino, Flora M. D.
    Brenol, Claiton V.
    Zerbini, Cristiano A. F.
    Garcia, Erika G.
    Akylbekova, Ermeg L.
    Rojo, Ricardo
    Ponce de Leon, Dario
    MEDICINE, 2018, 97 (31)
  • [23] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: LONG-TERM EXTENSION STUDY OUTCOMES IN AN AUSTRALIAN RHEUMATOID ARTHRITIS POPULATION
    Hall, S.
    Nash, P.
    Rischmueller, M.
    Bossingham, D.
    Cook, N.
    Witcombe, D.
    Kwok, K.
    Thirunavukkarasu, K.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 26 - 26
  • [24] Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation
    Kaine, Jeffrey
    Tesser, John
    DeMasi, Ryan
    Takiya, Liza
    Wang, Lisy
    Snyder, Mark
    Fan, Haiyun
    Wollenhaupt, Jurgen
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [25] Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
    Kostovic, Kresimir
    Gulin, Sandra J.
    Mokos, Zrinka B.
    Ceovic, Romana
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (11) : 1158 - 1167
  • [26] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: PATIENT REPORTED OUTCOMES IN AN AUSTRALIAN PHASE 3 RHEUMATOID ARTHRITIS STUDY POPULATION
    Hall, S.
    Nash, P.
    Rischmueller, M.
    Bossingham, D.
    Cook, N.
    Witcombe, D.
    Kwok, K.
    Thirunavukkarasu, K.
    INTERNAL MEDICINE JOURNAL, 2013, 43 : 11 - 11
  • [27] Tofacitinib: a new oral Janus kinase inhibitor for psoriasis
    Gimenez-Arnau, A. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (01) : 13 - 14
  • [28] Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme
    Curtis, J. R.
    Lee, E. B.
    Martin, G.
    Mariette, X.
    Terry, K. K.
    Chen, Y.
    Geier, J.
    Andrews, J.
    Kaur, M.
    Fan, H.
    Nduaka, C. I.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (04) : 614 - 622
  • [29] ANALYSIS OF NON-MELANOMA SKIN CANCER ACROSS THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Curtis, J.
    Lee, E. B.
    Martin, G.
    Mariette, X.
    Terry, K.
    Chen, Y.
    Geier, J.
    Andrews, J.
    Kaur, M.
    Fan, H.
    Nduaka, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 257 - 257
  • [30] Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme
    Curtis, Jeffery R.
    Lee, Eun Bong
    Martin, George
    Mariette, Xavier
    Terry, Ketti K.
    Chen, Yan
    Geier, Jamie
    Andrews, John
    Kaur, Mandeep
    Fan, Haiyun
    Nduaka, Chudy
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S11 - S11
12345